Contact Us

NMN Legal Dispute Updates: Legal Progress Sparks Hope

2024-11-01 | Irene, EffePharm

Summary
As the industry awaits a final decision on NMN’s regulatory status and the FDA’s response to the ongoing petition, one thing remains clear: NMN’s safety and effectiveness have been consistently demonstrated through years of use in the dietary supplement market.

Nicotinamide mononucleotide (NMN), a compound that has gained popularity in health and wellness circles for its potential anti-aging benefits, is currently at the center of a significant legal dispute. The Natural Products Association (NPA), an organization representing manufacturers and retailers of natural products, has initiated a lawsuit against the U.S. Food and Drug Administration (FDA). This lawsuit challenges the FDA’s classification of NMN as a dietary supplement, a designation that has implications for its sale, regulation, and marketing.

This legal action arises following a recent court ruling that has temporarily paused further legal proceedings. This stay grants the FDA additional time to thoroughly reevaluate a citizen petition that questions the classification and safety of NMN. The outcome of this legal dispute could have far-reaching implications for the dietary supplement industry and consumer access to NMN. The ruling temporarily pauses legal actions while the government has indicated it will not pursue enforcement actions against NMN dietary supplements under certain conditions [1].

Full Picture of the NMN FDA Ban

The National Poison Control Center (NPA) and the Food and Drug Administration (FDA) are currently in a dispute regarding the legality of NMN in the United States, a health ingredient being researched by Metro International Biotech LLC as a potential new drug. The company asserts that it has initiated significant clinical trials under an Investigational New Drug Application (IND) to investigate the effectiveness of NMN in treating various medical conditions, including Alzheimer’s disease, Friedreich’s ataxia, and kidney disease.
In March 2023, the NPA and the Alliance for Natural Health (ANH) submitted a petition urging the FDA to reconsider its position or exercise enforcement discretion. However, despite this petition, the FDA has yet to provide a definitive response, citing “competing agency priorities” that have hindered its ability to meet the 180-day decision timeline.
The NPA’s lawsuit challenges the FDA’s interpretation of the Dietary Supplement Health and Education Act (DSHEA), arguing that the agency has misapplied the “Drug Exclusion Clause” by wrongfully classifying NMN as a substance that cannot be marketed as a dietary supplement. According to the NPA, this interpretation not only threatens NMN but also poses risks to many other nutritional ingredients on the market [2] [3].

Recent Developments: Court Grants Stay

On October 24, 2024, a federal court issued a stay, temporarily halting legal proceedings while the FDA reviews a citizen petition concerning NMN, thereby allowing NMN supplements to remain available on the market without being the target of enforcement.
The agency is expected to provide a response by July 31, 2025. In a positive development, an FDA spokesperson indicated that the agency does not intend to take enforcement actions against NMN dietary supplements under certain conditions. This suggests that NMN products may continue to be sold without immediate regulatory concerns, provided they comply with existing regulations.

Positive Outlook for the NMN Market

Recent developments have provided significant relief to consumers worldwide who rely on NMN products for their health benefits. Dr. Jianjun Yu from EffePharm stated, “At EffePharm, we are dedicated to delivering clinically proven, high-quality NMN ingredients. While the dispute continues and we await the FDA’s response, we remain optimistic that our steadfast commitment will ensure UTHEVER® NMN continues to stand out as a trusted health option.”

What’s Next?

The ongoing situation surrounding NMN marks a pivotal moment for dietary supplements in the United States. With legal actions on hold and the FDA showing signs of a more flexible stance, the outlook for NMN products appears increasingly steady. One thing is clear: the health benefits and promise of NMN are acknowledged, securing its place as a viable choice for consumers worldwide.

Other Frequently Asked Questions:

Are NMN Supplement Safe?

Yes, NMN is a well-tolerated, safe ingredient. There are numerous concerns surrounding the FDA’s ban on NMN, with many assuming it may stem from safety issues. However, research has consistently shown that NMN is a safe and well-tolerated supplement, with no significant adverse effects reported in studies. The FDA’s decision to ban NMN is primarily rooted in legislative considerations rather than any legitimate safety concerns.

Is Liposomal NMN Better?

Yes, liposomal NMN can be more beneficial when compared to regular NMN, especially if you’re seeking enhanced absorption and efficiency. Just make sure to choose a reputable brand or liposome manufacturer with data to back up their formulation.

Where to find NMN clinical trials?

For most clinical studies, once they are registered, they are assigned a unique identifier in the United States. In the case of UTHEVER®, this identifier is NCT04228640 NMN. We have undertaken a comprehensive compilation of all clinical trials related to NMN, which is detailed in our white paper on NMN.

Want to find more in published clinical studies? Learn more through our NMN white paper!

For media inquiries or additional information, please contact EffePharm Marketing at marketing@effepharm.com.

About EffePharm:

Founded in 2017, EffePharm is a biotechnology company specializing in providing advanced wellness solutions to its global users. EffePharm is founded on the belief that everyone should have equal access to health and nutrition. EffePharm advocates for innovative bioscience applications, increased accessibility of nutrition, and improved quality of life. Committed to delivering efficacy-verified products to the market, EffePharm has established a portfolio of over 600 business partners worldwide, benefiting millions of consumers to thrive throughout their health and nutrition journeys.

More about UTHEVER® NMN

References

Long, J. (2024a, August 29). FDA faces new lawsuit from NPA over anti-aging ingredient NMN. Supplysidesj.com. https://www.supplysidesj.com/supplement-regulations/fda-faces-new-lawsuit-from-npa-over-anti-aging-ingredient-nmn

Long, J. (2024b, October 25). FDA telegraphs enforcement strategy against NMN supplements amid NPA lawsuit. Supplysidesj.com. https://www.supplysidesj.com/supplement-regulations/fda-telegraphs-enforcement-strategy-against-nmn-supplements-amid-npa-lawsuit

Long, J. (2024c, October 31). Judge pauses court case against FDA over NMN supplements. Supplysidesj.com. https://www.supplysidesj.com/supplements/judge-pauses-court-case-against-fda-over-nmn-supplements

Related news

Related Products

Schedule an Appointment with EffePharm's Experts

Contact us

Reference available upon request.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Information on this site is provided for informational purposes only. It is not meant to substitute for medical advice from your physician or other medical professional. You should not use the information contained herein to diagnose or treat a health problem or disease or prescribe any medication. Carefully read all product documentation. If you have or suspect that you have a medical problem, promptly contact your regular healthcare provider.

+86(021)5770 9202
deal@effepharm.com
Contact Us
Need live support?
Chat with us now